SB 537 (see companion bill HB 429) – Maryland

Status: Enacted
Year Introduced: 2021
Link: http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/SB0537?ys=2021RS

Requiring a pharmacist, or the pharmacist’s designee who is under certain supervision, to inform a consumer of the availability of a therapeutically equivalent brand name drug that is the lowest cost alternative to the originally prescribed drug or device and the cost difference between the equivalent drug or device and the prescribed drug; requiring a pharmacist to provide written notice, or to maintain a record that indicates a patient was notified in writing or orally, that the generic product is equivalent to the brand name product; etc.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found